12:00 AM
 | 
Nov 11, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Dermagraft: Development discontinued

Shire disclosed in its 3Q13 earnings that it discontinued development of ABH001 to treat epidermolysis bullosa as part of a pipeline prioritization. The product was in an open-label, international...

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >